Peptide Therapeutics for Chronic Kidney Disease
Kidney Peptide Therapeutics
24% kidney risk reduction
In the FLOW trial, semaglutide reduced major kidney disease events by 24% over 3.4 years in 3,533 patients with type 2 diabetes and chronic kidney disease.
Perkovic et al., NEJM, 2024
Perkovic et al., NEJM, 2024
View as imageChronic kidney disease (CKD) affects more than 850 million people worldwide and remains the 10th leading cause of death globally. Despite this burden, the therapeutic pipeline for CKD has been thin for decades, dominated by blood pressure control, RAAS inhibition, and glucose management. That changed dramatically in 2024 when the FLOW trial demonstrated that semaglutide, a GLP-1 receptor agonist peptide, reduced major kidney disease events by 24% in patients with type 2 diabetes and CKD.[1] But GLP-1 agonists are only part of the story. A growing pipeline of peptide therapeutics, from mitochondria-targeted peptides like SS-31 to endogenous repair factors like thymosin beta-4, is approaching the clinic for kidney diseases that current drugs cannot adequately treat. This article covers the full peptide pipeline for CKD, from approved agents to preclinical candidates. For focused coverage of specific approaches, see our articles on kidney-targeted peptide delivery and peptides for acute kidney injury.
Key Takeaways
- The FLOW trial showed semaglutide reduced major kidney disease events by 24% (HR 0.76) and slowed eGFR decline by 1.16 mL/min/1.73 m2 per year in 3,533 patients with T2D and CKD over 3.4 years (Perkovic et al., NEJM, 2024)
- GLP-1 receptor agonists protect kidneys through multiple mechanisms: reducing inflammation, oxidative stress, and fibrosis via beta-klotho-mediated ferroptosis inhibition, independent of their glucose-lowering effects (Tian et al., 2025)
- SS-31 (elamipretide), a mitochondria-targeted tetrapeptide, prevented cisplatin-induced acute kidney injury in mice by restoring mitochondrial membrane potential and reducing oxidative stress (Yang et al., Biomed Pharmacother, 2020)
- Thymosin beta-4 has emerged as a kidney repair candidate, with evidence of protective effects in ischemic AKI models and associations between circulating TB4 levels and AKI outcomes in sepsis patients (Zhang et al., 2021)
- Next-generation dual and triple agonist peptides targeting GLP-1/glucagon and GLP-1/GIP/glucagon receptors are in development for CKD with concurrent metabolic syndrome and fatty kidney disease (Kanbay et al., 2025)
- BPC-157, a gastric pentadecapeptide, showed kidney-protective effects in animal models of ischemia-reperfusion injury, though no human CKD data exist (Barisic et al., 2022)
Why CKD Needs Peptide Therapeutics
CKD progresses through a convergence of metabolic, hemodynamic, and inflammatory processes that current therapies only partially address. The standard of care, RAAS inhibitors (ACE inhibitors and ARBs), slow progression but do not stop it. SGLT2 inhibitors (dapagliflozin, empagliflozin) added a second protective layer, reducing CKD progression by 30-40% in trials like DAPA-CKD and EMPA-KIDNEY. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, provided a third option for diabetic kidney disease.
Despite these advances, a substantial residual risk of kidney failure persists. Among patients on optimal therapy with RAAS inhibition and an SGLT2 inhibitor, annual eGFR decline still averages 2-4 mL/min/1.73 m2, and a significant fraction progress to dialysis or transplant within a decade. The pathological processes driving this residual progression, including mitochondrial dysfunction, tubulointerstitial fibrosis, podocyte loss, and immune-mediated inflammation, are not fully addressed by existing drug classes.
The economics of kidney failure further motivate therapeutic development. A patient on dialysis costs healthcare systems $80,000-$100,000 per year in the US. Any therapy that delays dialysis initiation by even 2-3 years per patient would produce substantial cost savings and quality-of-life improvements. This economic calculus makes CKD a high-priority target for pharmaceutical development.
Peptide therapeutics are attractive for CKD for several structural reasons. Many key kidney-active signaling systems (the RAAS, the natriuretic peptide system, the incretin axis, the endothelin system) are already peptide-mediated. Peptides can be engineered for high receptor specificity, reducing off-target toxicity. And the kidney itself is a peptide processing organ: its proximal tubules reabsorb and metabolize circulating peptides through megalin and cubilin receptors, creating opportunities for kidney-selective drug targeting by engineering peptides that are preferentially taken up by renal tubular cells. For details on kidney-targeted delivery approaches, see our article on kidney-targeted peptide drug delivery.
The FLOW Trial: GLP-1 Agonists Reach the Kidney
Before 2024, no GLP-1 receptor agonist had been tested in a dedicated kidney outcomes trial. Post-hoc analyses of cardiovascular trials (SUSTAIN-6, LEADER, SELECT) had suggested renal benefits, but the evidence was indirect. The FLOW trial changed that.
Perkovic et al. (2024) randomized 3,533 patients with type 2 diabetes and CKD (eGFR 25-75 mL/min/1.73 m2 with albuminuria) to subcutaneous semaglutide 1.0 mg weekly or placebo, with a median follow-up of 3.4 years. The trial was stopped early for efficacy.[1]
Primary outcome
Major kidney disease events (sustained eGFR decline of 50% or more, kidney failure, or kidney-related death) occurred in 331 patients in the semaglutide group versus 410 in the placebo group: a 24% relative risk reduction (hazard ratio 0.76, 95% CI 0.66-0.88).
Secondary outcomes
The annual rate of eGFR decline was 1.16 mL/min/1.73 m2 slower with semaglutide. Cardiovascular death was reduced by 29% (HR 0.71). Major adverse cardiovascular events were reduced by 18%. The benefits were consistent across subgroups defined by baseline eGFR, albuminuria level, and concomitant SGLT2 inhibitor use.[1]
Subgroup analysis by CKD severity
Tuttle et al. (2026) performed a prespecified analysis of FLOW outcomes by CKD severity. Semaglutide's kidney and survival benefits extended across the full range of CKD severity enrolled in the trial, including patients with eGFR below 45 mL/min/1.73 m2. The absolute risk reduction was largest in patients with the most advanced CKD, where baseline event rates are highest.[3]
These results established semaglutide as the first GLP-1 receptor agonist with proven kidney-protective effects from a dedicated renal outcomes trial. For broader context on GLP-1 cardiovascular effects, see our article on GLP-1 drugs and heart disease.
How GLP-1 Agonists Protect Kidneys
The mechanisms by which GLP-1 receptor agonists protect kidneys extend well beyond glucose control.
Inflammation and fibrosis reduction
GLP-1 receptors are expressed in the kidney, particularly in glomerular endothelial cells and proximal tubular cells. Activation of these receptors reduces inflammatory cytokine production (IL-6, TNF-alpha, MCP-1), suppresses NF-kB signaling, and attenuates tubular and interstitial fibrosis. These anti-inflammatory effects appear to be independent of the glycemic improvements produced by GLP-1 agonists.[2]
Beta-klotho and ferroptosis
Tian et al. (2025) identified a novel mechanism: GLP-1 receptor agonists upregulate beta-klotho expression in kidney tissue, which inhibits ferroptosis (iron-dependent programmed cell death) in tubular epithelial cells. In diabetic kidney disease models, GLP-1 RA treatment restored beta-klotho levels, reduced lipid peroxidation, and preserved tubular cell viability.[4] Ferroptosis has emerged as a key pathological process in diabetic nephropathy, and its suppression by GLP-1 agonists adds a mechanistic layer beyond the traditional hemodynamic and metabolic explanations.
Hemodynamic effects
GLP-1 agonists reduce sodium reabsorption in the proximal tubule, increase natriuresis, and modestly lower glomerular pressure. They also reduce body weight and blood pressure, both of which contribute to long-term kidney protection. The combination of metabolic, hemodynamic, and anti-inflammatory effects likely explains why GLP-1 agonists produce kidney benefits that exceed what glucose lowering alone would predict. In the FLOW trial, the kidney protection observed with semaglutide was similar regardless of baseline HbA1c, reinforcing that the mechanism is not purely glycemic.[1]
Cardiorenal integration
Apperloo et al. (2026) reviewed the cardiorenal protective effects of GLP-1-based therapeutics, emphasizing that CKD and cardiovascular disease share metabolic drivers (insulin resistance, inflammation, lipotoxicity) that GLP-1 agonists address simultaneously. The concept of "cardiorenal metabolic syndrome" positions GLP-1 agonists as multi-organ protective agents rather than purely glycemic drugs.[11]
Next-Generation Peptide Agonists for CKD
Dual and triple receptor agonists
Kanbay et al. (2025) reviewed the emerging concept of "fatty kidney disease," where ectopic lipid accumulation in renal tissue drives inflammation and fibrosis analogous to fatty liver disease. Dual GLP-1/glucagon agonists (survodutide, cotadutide) and triple GLP-1/GIP/glucagon agonists (retatrutide) may address this pathology by combining GLP-1's anti-inflammatory effects with glucagon's lipid-oxidizing properties. These agents are in clinical trials for metabolic syndrome but have not yet been tested in dedicated CKD trials.[7]
Alicic et al. (2026) provided a comprehensive review in Nature Reviews Nephrology of GLP-1 receptor agonists and next-generation metabolic hormone therapies in CKD, including tirzepatide (GLP-1/GIP dual agonist), survodutide (GLP-1/glucagon dual agonist), and other multi-receptor peptides. The review identified kidney fibrosis reduction, podocyte protection, and tubular regeneration as key mechanisms that may extend beyond what current mono-agonists achieve.[2]
Mitochondria-Targeted Peptides: SS-31
SS-31 (elamipretide, Bendavia) is a cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, a phospholipid essential for electron transport chain function. Mitochondrial dysfunction is a central pathological feature of both acute and chronic kidney disease: when mitochondria fail, tubular epithelial cells lose energy production capacity, generate excess reactive oxygen species, and undergo apoptosis.
AKI protection
Yang et al. (2020) demonstrated that SS-31 prevented cisplatin-induced acute kidney injury in mice by restoring mitochondrial membrane potential, reducing ROS production, inhibiting NLRP3 inflammasome activation, and preserving tubular cell structure. Treated mice showed lower serum creatinine, less tubular necrosis, and reduced inflammatory cytokines compared to untreated controls.[5]
Liu et al. (2019) developed a pH-responsive nanoparticle delivery system for SS-31 that enhanced its accumulation in injured kidneys by exploiting the acidic microenvironment of ischemic tissue. The targeted delivery improved SS-31's protective effects in an ischemia-reperfusion AKI model.[10]
Why mitochondria matter in CKD
The kidney is the most energy-demanding organ per gram of tissue after the heart. Proximal tubular cells depend almost entirely on mitochondrial oxidative phosphorylation for energy, with minimal glycolytic capacity. When mitochondria become damaged (by ischemia, toxins, hyperglycemia, or aging), tubular cells cannot sustain the active transport processes that underlie filtrate reabsorption. The result is tubular atrophy, interstitial fibrosis, and progressive nephron loss.
CKD patients show systemic mitochondrial dysfunction, with reduced mitochondrial DNA copy number, lower respiratory chain complex activity, and elevated oxidative stress markers in kidney biopsies. A peptide that restores mitochondrial function could address a root cause of progression rather than just treating its downstream consequences.
Clinical development
Elamipretide has been tested in clinical trials for heart failure (Barth syndrome), age-related macular degeneration, and primary mitochondrial myopathy, but has not yet entered kidney-specific clinical trials. The preclinical kidney data is encouraging, but the path from mouse AKI protection to human CKD therapy remains long and uncertain. AKI models use acute, severe injuries that are mechanistically distinct from the slow, multicausal progression of CKD. A peptide that prevents cisplatin toxicity in a mouse kidney may not slow diabetic nephropathy in a human over five years. For more on peptides that protect kidneys during acute injury, see our article on peptides for acute kidney injury.
Thymosin Beta-4: The Repair Peptide
Thymosin beta-4 (TB4) is a 43-amino-acid peptide that sequesters monomeric actin, regulates cell migration, and promotes tissue repair. Its role in kidney biology has attracted growing interest.
Mason et al. (2023) reviewed TB4's pathophysiological role in the kidney glomerulus, finding that TB4 is expressed in podocytes and mesangial cells and plays a role in maintaining glomerular filtration barrier integrity. In disease states, TB4 expression patterns change in ways that suggest both protective and potentially pathological roles depending on the context.[9]
Zhang et al. (2021) examined circulating thymosin beta-4 levels in 370 patients with sepsis and found that lower TB4 levels at admission were independently associated with a higher risk of developing acute kidney injury and 28-day mortality. This observational finding suggests TB4 may serve as both a biomarker and a potential therapeutic target in sepsis-associated AKI.[6]
Di et al. (2026) published a comprehensive review of thymosin beta-4 as an emerging therapeutic candidate for kidney diseases, covering its anti-inflammatory, anti-fibrotic, and pro-regenerative mechanisms. The review highlighted TB4's ability to reduce renal fibrosis through TGF-beta/Smad pathway modulation and its promotion of tubular cell regeneration after injury.[8]
All TB4 kidney data remain preclinical or observational. No randomized controlled trial of TB4 for kidney disease has been reported.
Aksu 2021: ischemic AKI model
In a complementary study, Aksu et al. (2021) demonstrated that TB4 administration reduced kidney injury scores, lowered serum creatinine, and decreased tubular apoptosis in a rat ischemia-reperfusion AKI model. TB4 appeared to act through multiple mechanisms: reducing oxidative stress (lowering MDA, raising SOD and catalase levels), suppressing inflammatory cytokines (TNF-alpha, IL-1beta), and promoting cell survival via Akt/GSK-3beta pathway activation. The consistency of TB4's protective effects across different AKI models (cisplatin, ischemia, sepsis) strengthens the biological plausibility of its kidney-protective properties, even though no single study is definitive.
The therapeutic potential of TB4 for CKD specifically (rather than AKI) has not been directly tested. CKD involves chronic fibrosis, podocyte depletion, and tubular atrophy over years, pathological processes that may or may not respond to the same repair mechanisms that TB4 activates in acute injury. Mason's 2023 glomerular work suggests TB4 has a homeostatic role in normal kidney maintenance, which could support a CKD application, but this hypothesis requires prospective testing.
Natriuretic Peptides and Kidney Interactions
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are cardiac-derived peptides that promote natriuresis, vasodilation, and RAAS suppression. They have long been recognized as kidney-active hormones, but their therapeutic potential in CKD has been limited by short half-lives and hypotensive side effects.
Inoue et al. (2025) demonstrated an unexpected connection: deletion of the natriuretic peptide/guanylyl cyclase-A signaling pathway in mice exacerbated diabetic kidney disease, and finerenone (a mineralocorticoid receptor antagonist) partially compensated for this loss. The study suggests that natriuretic peptide signaling is a protective factor in diabetic nephropathy, and its impairment may contribute to disease progression.[12]
Endothelin Receptor Antagonists: A Peptide System Target
Endothelin-1 (ET-1), a 21-amino-acid vasoconstrictor peptide produced by endothelial cells, is among the most potent vasoconstrictors known. In the kidney, ET-1 promotes vasoconstriction of the afferent and efferent arterioles, stimulates mesangial cell contraction, increases sodium reabsorption, and drives fibrosis through direct fibroblast activation.
Endothelin receptor antagonists (ERAs) target this peptide system rather than administering a peptide directly. Atrasentan, a selective ETA receptor antagonist, reduced albuminuria by 35% in the SONAR trial of diabetic kidney disease patients on RAAS inhibitors. Zibotentan, another ETA antagonist, is being studied in combination with dapagliflozin in the ZENITH-CKD trial for non-diabetic CKD. Sparsentan, a combined ETA and angiotensin receptor blocker, received accelerated FDA approval in 2023 for IgA nephropathy based on albuminuria reduction in the PROTECT trial.
These agents work by blocking the effects of endogenous endothelin peptides rather than replacing them. The approach illustrates that peptide systems can be therapeutic targets even when the peptide itself cannot be delivered as a drug. The endothelin system's involvement in kidney disease reinforces the centrality of peptide signaling in renal pathophysiology.
The main safety concern with ERAs is fluid retention due to the role of endothelin in renal sodium handling. This has historically caused heart failure events in clinical trials, and it explains why highly selective ETA antagonists (which spare the ETB receptor's natriuretic function) have shown better safety profiles than non-selective agents.
Peptide Biomarkers in CKD
Beyond therapeutics, peptide-based biomarkers are reshaping CKD diagnosis and monitoring. Urinary peptidomic profiles, which measure hundreds of small peptides in urine, can classify CKD subtypes and predict progression risk better than albuminuria alone.
CKD273, a classifier based on 273 urinary peptide fragments (mostly collagen and uromodulin degradation products), predicts progression from normoalbuminuria to microalbuminuria and from early CKD to kidney failure. In prospective studies, CKD273 identified high-risk patients 3-5 years before conventional biomarkers showed abnormalities.
Kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and uromodulin are protein/peptide biomarkers that provide different information than creatinine-based eGFR: KIM-1 reflects proximal tubular injury, NGAL indicates distal tubular stress, and uromodulin levels correlate with functioning nephron mass. The combination of these peptide biomarkers with traditional measures is moving toward clinical adoption for AKI risk stratification and CKD progression monitoring.
These biomarker advances are relevant to the therapeutic pipeline because they may enable earlier intervention. If a peptide biomarker can identify CKD progressors years before clinical endpoints occur, the window for peptide therapeutics to modify disease course becomes substantially wider.
BPC-157: Preclinical Kidney Data
BPC-157, a stable gastric pentadecapeptide, has shown kidney-protective effects in animal models. Barisic et al. (2022) demonstrated that BPC-157 attenuated kidney injury in a rat model of myocardial infarction complicated by renal ischemia. The peptide reduced serum creatinine, decreased histological kidney damage, and appeared to preserve renal blood flow, potentially through its effects on the NO system and endothelial function.[13]
These findings are consistent with BPC-157's broader cytoprotective profile observed across multiple organ systems. No human studies of BPC-157 for kidney disease exist, and the peptide has not entered clinical trials for any kidney indication. For broader context on BPC-157's evidence base, see our article on BPC-157: what the research shows.
Evidence Limitations
The peptide therapeutics pipeline for CKD faces several critical evidence gaps.
GLP-1 agonist kidney data, while strong from FLOW, is limited to patients with type 2 diabetes. Whether GLP-1 agonists protect kidneys in non-diabetic CKD (IgA nephropathy, polycystic kidney disease, lupus nephritis) is unknown. The FLOW trial enrolled patients on stable RAAS inhibition and, in many cases, SGLT2 inhibitors, making it difficult to isolate semaglutide's independent kidney effect from the background of established renal protection.[1]
SS-31 and TB4 kidney data remain entirely preclinical for CKD applications. The gap between demonstrating kidney protection in mouse models (which typically use acute injury models) and proving benefit in human CKD (a slowly progressive disease over years to decades) is enormous. Preclinical AKI models do not reliably predict CKD outcomes.
BPC-157 kidney evidence is limited to a single animal study in a combined cardiac-renal injury model. No dose-ranging, pharmacokinetic, or mechanism-of-action studies specific to kidney tissue have been published.
The dual and triple agonist peptides (survodutide, retatrutide) are in clinical development for metabolic indications but have not entered CKD-specific trials. Their potential kidney benefits are extrapolated from GLP-1 mono-agonist data and mechanistic reasoning, not direct evidence.
The natriuretic peptide system, while clearly involved in kidney physiology, has not yielded a viable CKD therapeutic. ANP and BNP have short half-lives (minutes), cause dose-limiting hypotension, and are difficult to dose-titrate. Nesiritide (recombinant BNP) was approved for acute heart failure but showed no kidney benefit and raised safety concerns. Designer natriuretic peptide analogs with improved pharmacokinetics are in early development but none have reached CKD trials.[12]
A broader concern across the entire peptide CKD pipeline is that most preclinical models use young, otherwise healthy animals with a single acute insult. Human CKD typically involves older patients with multiple comorbidities (diabetes, hypertension, cardiovascular disease) and years of accumulated kidney damage. Translational failure rates from preclinical kidney models to human trials remain high. For coverage of the delivery challenges involved in getting peptide drugs to the kidney specifically, see our article on kidney-targeted peptide delivery.
The Bottom Line
The peptide therapeutics pipeline for chronic kidney disease has expanded from a single class (GLP-1 agonists) to a diverse set of candidates targeting different aspects of kidney pathology. The FLOW trial's 24% reduction in major kidney events with semaglutide is the strongest evidence to date, but mitochondria-targeted peptides (SS-31), repair peptides (thymosin beta-4), and next-generation multi-receptor agonists represent distinct mechanistic approaches. Most non-GLP-1 candidates remain preclinical, and the translation gap from acute injury models to chronic disease therapeutics remains the field's central challenge.